Diffuse Cutaneous Aphthosis After Combined Targeted Cancer Therapies and Responsive to Pentoxifylline

被引：0
|
作者：
Larocca, Cecilia A. [1 ,2 ]
Fay, Christopher J. [1 ,2 ]
Hirner, Jesse P. [3 ]
Meyerhardt, Jeffrey A. [4 ]
Cleary, James M. [4 ]
Dewan, Anna K. [5 ]
LeBoeuf, Nicole R. [1 ,2 ]
机构：
[1] Dana Farber Canc Inst, Ctr Cutaneous Oncol, Dept Dermatol, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, 450 Brookline Ave, Boston, MA 02215 USA
[3] Univ Missouri Hlth Care, Dept Dermatol, Columbia, MO USA
[4] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[5] Vanderbilt Univ, Med Ctr, Dept Dermatol, Nashville, TN USA
来源：
JAMA DERMATOLOGY | 2023年 / 159卷 / 10期
关键词：
D O I：
10.1001/jamadermatol.2023.2649
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
This case series describes 3 patients who developed cutaneous aphthosis while taking an epidermal growth factor receptor inhibitor in combination with an MEK inhibitor.
引用
收藏
页码：1136 / 1139
页数：4
相关论文
共 50 条
  • [21] Cardiovascular toxicities after anthracycline and VEGF-targeted therapies in adolescent and young adult cancer survivors
    Jeannette R. Wong-Siegel
    Robert J. Hayashi
    Randi Foraker
    Joshua D. Mitchell
    Cardio-Oncology, 9
  • [22] Risk of Cancer After Initiation of Targeted Therapies in Patients With Rheumatoid Arthritis and a Prior Cancer: Systematic Review With Meta-Analysis
    Wetzman, Amelie
    Lukas, Cedric
    Gaujoux-Viala, Cecile
    Mamtani, Ronac
    Barnetche, Thomas
    Combe, Bernard
    Morel, Jacques
    Szafors, Paulina
    ARTHRITIS CARE & RESEARCH, 2023, 75 (02) : 260 - 271
  • [23] Incidence of Skin Cancer in Patients With Chronic Inflammatory Cutaneous Diseases on Targeted Therapies: A Systematic Review and Meta-Analysis of Observational Studies
    Crisafulli, Salvatore
    Bertino, Lucrezia
    Fontana, Andrea
    Calapai, Fabrizio
    Ingrasciotta, Ylenia
    Berretta, Massimiliano
    Trifiro, Gianluca
    Guarneri, Claudio
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [24] Cutaneous eruption with reactive endothelial atypia due to emerging targeted cancer therapies: Report of two cases with clinico-pathologic correlation
    Moya-Martinez, Cristina
    Torre-Castro, Juan
    Farina-Sabaris, M. Carmen
    Santiago Sanchez-Mateos, Diana
    Erana-Tomas, Itziar
    Jo-Velasco, Margarita
    Requena, Luis
    JOURNAL OF CUTANEOUS PATHOLOGY, 2021, 48 (06) : 789 - 794
  • [25] Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review
    Marjanski, Tomasz
    Dziedzic, Robert
    Kowalczyk, Anna
    Rzyman, Witold
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (22)
  • [26] Anti-EGFR targeted therapies combined with chemoradiotherapy in patients with locally advanced non-small cell lung cancer
    Arpin, D.
    Pourel, N.
    ONCOLOGIE, 2012, 14 (05) : 275 - 281
  • [27] pH-responsive upconversion mesoporous silica nanospheres for combined multimodal diagnostic imaging and targeted photodynamic and photothermal cancer therapy
    Loganathan, Palanikumar
    Kalmouni, Mona
    Houhou, Tatiana
    Abdullah, Osama
    Ali, Liaqat
    Straubinger, Rainer
    Thomas, Sneha
    Afzal, Ahmed J.
    Barrera, Francisco N.
    Magzoub, Mazin M.
    BIOPHYSICAL JOURNAL, 2024, 123 (03) : 436A - 436A
  • [28] pH-Responsive Upconversion Mesoporous Silica Nanospheres for Combined Multimodal Diagnostic Imaging and Targeted Photodynamic and Photothermal Cancer Therapy
    Palanikumar, L.
    Kalmouni, Mona
    Houhou, Tatiana
    Abdullah, Osama
    Ali, Liaqat
    Pasricha, Renu
    Straubinger, Rainer
    Thomas, Sneha
    Afzal, Ahmed Jawaad
    Barrera, Francisco N.
    Magzoub, Mazin
    ACS NANO, 2023, 17 (19) : 18979 - 18999
  • [29] Combined oral alitretinoin and narrowband UVB treatment of cutaneous T cell lymphoma: favourable response after multiple ineffective systemic therapies
    Motschenbacher, Stephanie
    Buder, Kristina
    Goebeler, Matthias
    Kerstan, Andreas
    EUROPEAN JOURNAL OF DERMATOLOGY, 2012, 22 (06) : 803 - 804
  • [30] Combined targeted therapies for advanced triple negative breast cancer: A phase II trial of nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and erlotinib
    Specht, J. M.
    Gadi, V. K.
    Gralow, J. R.
    Korde, L. A.
    Linden, H. M.
    Salazar, L. G.
    Rodler, E. T.
    Cundy, A.
    Buening, B. J.
    Baker, K. K.
    Redman, M. W.
    Kurland, B. F.
    Garrison, M. A.
    Smith, J. C.
    vanhaelst, C.
    Anderson, J. E.
    CANCER RESEARCH, 2017, 77
12345